SCHEMBL16500486

SCHEMBL16500486

CCC(=O)NCCCCCCOC

nearest known ligand 0.72

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.68
KMT2A Q03164 1/20 0.68
TSHR P16473 1/20 0.60
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RECQL P46063 2/20 0.49
CASP2 P42575 1/20 0.47
EPHX1 P07099 1/20 0.47
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
FAAH O00519 1/20 0.44
ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31036065 1.00 MEN1 (0.68) MEN1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL16384294 1.00 MEN1 (0.68) MEN1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL4547630 0.98 MEN1 (0.71) MEN1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL3821431 0.92 TSHR (0.70) MEN1KMT2ATSHRALDH1A1RECQL
SCHEMBL11758762 0.85 MEN1 (0.94) MEN1KMT2AALDH1A1SMN1; SMN2RECQL
SCHEMBL21765846 0.85 MEN1 (0.94) MEN1KMT2AALDH1A1SMN1; SMN2RECQL
SCHEMBL9259257 0.85 MEN1 (0.94) MEN1KMT2AALDH1A1SMN1; SMN2RECQL
SCHEMBL26553980 0.85 CASP2 (0.69) MEN1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL22856469 0.84 MEN1 (0.68) MEN1KMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL22525938 0.84 MEN1 (0.57) MEN1KMT2ATSHRALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091985-A1 COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE DTX PHARMA, INC. (US) 2023-05-25 WO disclosed
WO-2021086069-A1 COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT 재단법인 대구경북첨단의료산업진흥재단 2021-05-06 WO disclosed
EP-0710667-B1 Modified oligonucleotides, their preparation and their use ROCHE DIAGNOSTICS GMBH (DE) 2011-12-14 EP disclosed